Kintegral Advisory LLC Cuts Stock Position in Cencora, Inc. (NYSE:COR)

Kintegral Advisory LLC reduced its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 32.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,162 shares of the company's stock after selling 5,965 shares during the quarter. Kintegral Advisory LLC's holdings in Cencora were worth $3,382,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Hoey Investments Inc. acquired a new stake in shares of Cencora in the first quarter valued at approximately $28,000. Banque Transatlantique SA acquired a new stake in shares of Cencora in the fourth quarter valued at approximately $29,000. SBI Securities Co. Ltd. acquired a new stake in shares of Cencora in the fourth quarter valued at approximately $30,000. Vermillion Wealth Management Inc. acquired a new stake in shares of Cencora in the fourth quarter valued at approximately $38,000. Finally, OFI Invest Asset Management acquired a new stake in shares of Cencora in the fourth quarter valued at approximately $41,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Trading Up 1.7%

Shares of COR traded up $5.06 on Friday, hitting $296.23. 614,990 shares of the stock traded hands, compared to its average volume of 1,506,788. The company has a quick ratio of 0.52, a current ratio of 0.87 and a debt-to-equity ratio of 6.01. The firm has a market capitalization of $57.42 billion, a P/E ratio of 34.37, a P/E/G ratio of 1.47 and a beta of 0.57. The stock's 50 day moving average is $291.12 and its two-hundred day moving average is $267.51. Cencora, Inc. has a 1 year low of $218.65 and a 1 year high of $309.35.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, topping analysts' consensus estimates of $4.07 by $0.35. The company had revenue of $75.50 billion for the quarter, compared to the consensus estimate of $75.41 billion. Cencora had a net margin of 0.55% and a return on equity of 344.71%. Cencora's revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the firm posted $3.80 earnings per share. As a group, sell-side analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Friday, May 16th were paid a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.74%. The ex-dividend date of this dividend was Friday, May 16th. Cencora's dividend payout ratio is currently 25.52%.

Wall Street Analysts Forecast Growth

COR has been the topic of several research reports. Wells Fargo & Company upgraded shares of Cencora from an "equal weight" rating to an "overweight" rating and increased their price target for the company from $274.00 to $337.00 in a research report on Tuesday, June 3rd. Bank of America increased their price target on shares of Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research report on Friday, April 11th. Morgan Stanley set a $288.00 price target on shares of Cencora in a research report on Tuesday, April 15th. Jefferies Financial Group increased their price target on shares of Cencora from $275.00 to $300.00 and gave the company a "hold" rating in a research report on Monday, June 30th. Finally, Wall Street Zen raised shares of Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $306.33.

Insider Buying and Selling

In other Cencora news, Chairman Steven H. Collis sold 14,579 shares of the stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $292.62, for a total transaction of $4,266,106.98. Following the transaction, the chairman owned 311,913 shares of the company's stock, valued at $91,271,982.06. This trade represents a 4.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Robert P. Mauch sold 4,969 shares of the stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the transaction, the chief executive officer directly owned 47,582 shares in the company, valued at approximately $13,766,900.06. This represents a 9.46% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 34,127 shares of company stock worth $9,812,296. 10.80% of the stock is currently owned by insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.